1. Home
  2. MDGL vs LPX Comparison

MDGL vs LPX Comparison

Compare MDGL & LPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • LPX
  • Stock Information
  • Founded
  • MDGL 2011
  • LPX 1973
  • Country
  • MDGL United States
  • LPX United States
  • Employees
  • MDGL N/A
  • LPX N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • LPX Forest Products
  • Sector
  • MDGL Health Care
  • LPX Basic Materials
  • Exchange
  • MDGL Nasdaq
  • LPX Nasdaq
  • Market Cap
  • MDGL 6.1B
  • LPX 6.8B
  • IPO Year
  • MDGL N/A
  • LPX N/A
  • Fundamental
  • Price
  • MDGL $417.43
  • LPX $90.26
  • Analyst Decision
  • MDGL Strong Buy
  • LPX Buy
  • Analyst Count
  • MDGL 10
  • LPX 7
  • Target Price
  • MDGL $474.67
  • LPX $111.43
  • AVG Volume (30 Days)
  • MDGL 329.8K
  • LPX 749.7K
  • Earning Date
  • MDGL 10-30-2025
  • LPX 11-04-2025
  • Dividend Yield
  • MDGL N/A
  • LPX 1.19%
  • EPS Growth
  • MDGL N/A
  • LPX N/A
  • EPS
  • MDGL N/A
  • LPX 4.23
  • Revenue
  • MDGL $515,547,000.00
  • LPX $2,880,000,000.00
  • Revenue This Year
  • MDGL $394.12
  • LPX N/A
  • Revenue Next Year
  • MDGL $57.74
  • LPX $7.88
  • P/E Ratio
  • MDGL N/A
  • LPX $22.22
  • Revenue Growth
  • MDGL 3421.98
  • LPX N/A
  • 52 Week Low
  • MDGL $200.63
  • LPX $78.82
  • 52 Week High
  • MDGL $457.16
  • LPX $122.87
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 54.19
  • LPX 40.43
  • Support Level
  • MDGL $418.36
  • LPX $94.78
  • Resistance Level
  • MDGL $440.90
  • LPX $97.88
  • Average True Range (ATR)
  • MDGL 13.63
  • LPX 2.60
  • MACD
  • MDGL -5.66
  • LPX -0.72
  • Stochastic Oscillator
  • MDGL 4.56
  • LPX 1.87

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About LPX Louisiana-Pacific Corporation

Louisiana-Pacific is primarily an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The company is largely exposed to the North American housing market but has also established capacity in Brazil and Chile.

Share on Social Networks: